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ABSTRACT
Background: In this study, we investigated if a combination of the nutr aceutical supplement, EvenFlo and
folic acid will be superior to the standard stand-alone use of folic acid.
Methods: We conducted a r andomized double-blind, active-controlled, clinical trial. A total of 70 subjects with
SCD ages 5-12 years were enrolled into the study with 35 in the intervention group and 35 in the control group;
61 completed the trial (32 from the intervention group and 29 from the control group).
Results: Par ticipants in the inter vention gr oup wer e significantly less likely to exper ience cr ises compar ed
to subjects in the control group. None of the subjects in the intervention group experienced any form of vasoocclusive crisis (VOC) compared to 93.1% of the subjects in the controlled group. Additionally, the intervention
group experienced a significantly higher increase in their hemoglobin concentration from baseline (2.92 g/dL,
95% CI [2.33, 3.51]) compared the control group (1.77 g/dL, 95% CI [1.00, 2.54]). The intervention group experienced a significantly higher increase in their mean weight from baseline (4.47 Kg, 95% CI [4.02, 4.92]) while the
control group experienced a decrease (-1.05 Kg, 95% CI [-1.60, -0.51]).
Conclusions: EvenFlo is a nutr itional supplement effective in the management of SCD when combined with
folic acid; its beneficial effect would be useful in boosting the hemoglobin concentration and weight indices individuals with SCD as well as and in limiting the crises they suffered.
Keywords: sickle cell anemia, sickle cell disease, SCD, EvenF lo, nutraceutical supplement, randomized
controlled trial, RCT.
INTRODUCTION
Sickle cell disease (SCD) is a group of red blood
cell abnormalities that are inherited. The disease
results from mutation in the HBB (Hemoglobin, Beta)
which helps in making the beta-globin protein. Heterozygotes produce a mixture of normal hemoglobin and
sickle hemoglobin. Homozygotes only produce abnormal beta chains that make sickle hemoglobin, and this
results in the clinical syndrome of sickle-cell disease
(Ralston et al., 2018). When the sickle hemoglobin is
deoxygenated, the molecules of hemoglobin polymerize to form pseudo crystalline structures known as
‘tactoids.’ These distort the red cell membrane and
produce characteristic sickle-shaped cells (Ralston et
al., 2018).

Sickle cell disease affects millions of people
worldwide and affects people from several races and
groups including Hispanics, South Asians, Caucasians
from southern Europe, and people from Middle Eastern countries. Altogether, over 100 million people
worldwide carry the sickle cell trait (American Society
of Hematology [ASH], 2017; Piel, Hay, Gupta, Weatherall, & Williams, 2013). The disease is the most predominant monogenic disorder in humans worldwide
and the single most common genetic disease in the
United States, affecting approximately 100,000 Americans (Centers for Disease Control and Prevention
[CDC], 2019).
SCD occurs in approximately 300,000 births annually. Nigeria, the Democratic Republic of Congo
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and India top the list of countries with SCD births. The
vast majority of SCD births occur in sub Saharan Africa where at least 240,000 children are born with the
disease every year (Piel et al., 2013; Williams, 2016).
An estimated 4,500 of these children are born in Kenya (Grosse et al., 2011). Worldwide, an approximate
50-90% of children born with SCD die undiagnosed
before their 5th birthday (Grosse et al., 2011; Marsh,
Kamuya, & Molyneux, 2011; World Health Organization [WHO], 2010).

Given opportunities that exist to help SCD patients better manage their disease, EvenFlo nutritional
supplement was developed as treatment and prevention
options. The present study explored the efficacy of
EvenFlo, a nutraceutical supplement, in conjunction
with the traditional use of folic acid by conducting a
clinical trial to test the effectiveness of combined use
of these active agents.

Once clinically diagnosed, common treatment of
sickle cell disease involves patients initiating daily
doses of folic acid tablets to boost their hemoglobin
concentration levels even as there is not strong evidence of this (Dixit et al., 2018). Antibiotic prophylaxis (penicillin V for those not allergic) are also
sometimes administered to prevent against pneumococcal infection. Other treatments include use of Hydroxyurea (Borhade & Kondamudi, 2020), and blood
and bone marrow transplant (CDC, 2020).

EVENFLO

Presentation of sickle cell disease, or sickling, is
precipitated by hypoxia, acidosis, dehydration and
infection. Irreversibly sickled cells have a shortened
survival (normal cells last 120 days) which may result
in a number of acute syndromes termed ‘crises’ and
chronic organ damage. Vaso-occlusive crises (VOCs)
are a type of several types of crises and presents with
severe pain with somewhat uncommon objective clinical signs and are mostly identified through experience
and subjective methods (Borhade & Kondamudi,
2020). In the US, VOCs lead to more about 197,000
ED visits and 356 million dollars spent on pain management every year (Lentz & Kautz, 2017).
Apart from the crises experienced by individuals
with SCD, the disease has been shown to be associated
with factors such as underweight and growth deficit,
stunting, and wasting in children. Others include clinical variables such as hemoglobin concentration,
disease progression, nutritional factors and the type of
treatment implemented (Kazadi, Ngiyulu, GiniEhungu, Mbuyi-Muamba, & Aloni, 2017; Dos, De,
Ivo, & Cople, 2018). Crises from SCD are generally
managed by aggressive intravenous rehydration, oxygen therapy, adequate analgesia (which often requires
opiates) and antibiotics (Jain, Bakshi, & Krishnamurti,
2017; Yawn & John-Sowah, 2015).
Despite the options available for the treatment of
SCD, there is still a lack of reprieve from the crises
experienced by SCD patients and the frequency of
crises remains high among those who take the conventional drugs to prevent the crises, hence, morbidity and
mortality rates of patients remains high (Grosse, et al.,
2011; Piel et al., 2013; Pule & Wonkam, 2014; World
Health Organization, 2010). Thus, the United Nations
General Assembly on 22nd December, 2008, adopted
a resolution recognizing sickle cell anemia as a public
health problem (United Nation, 2009).
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EvenFlo is a nutritional supplement formulated to
help manage SCD, particularly, the crises that SCD
patients suffer and associated pain. The supplement
was formulated to promote bone marrow cells to enter
the cell cycle and boost the production of red blood
cells leading to significantly increased IL-3 secretion,
and significantly inhibited IFN-γ secretion. This leads
to increased hemoglobin concentration, and hematocrit
(Guo & Wang, 2006; Hsu, Ho, & Lin, 1996; Liu et al.,
2014). An earlier observation study conducted on
EvenFlo appears to show a significant proportion of
participants to have improved life style in the form of
improvement of appetite, anemia, general health status, pain management, and weight management
(Anicet et al., 2019).
The active components of EvenFlo that make it
suitable of significantly limiting SCD crises by aiding
red blood cell production leading to increased hemoglobin concentration and better weight management
include atractylodes, codonopsis, corydalis, dong quai,
jujube, licorice root or Szechuan lovage, poria,
rehmannia root, salvia miltiorrhiza, and white peony.
Atractylodes are present in different forms including atractylenolactam, biatractylolide and atractylone.
Atractylenolactam exhibits anti-inflammatory activity
and has anti-inflammatory, anticoagulation and gastrointestinal repair effects (Hoang le et al., 2016; Ji, Chen
& Wang, 2016; Song et al., 2017; Tang, Liao, Huang,
Lin, & Wu, 2017). Biatractylolide has a neuroprotective effect on glutamate-induced injury (Zhu et al.,
2017). Atractylone have anti-microbial and antiinflammatory activities (Wu et al., 2020). Codonopsis
has active ingredients that helps in the replenishment
of vital energy deficiency, strengthening the immune
system, improving poor gastrointestinal function, gastric ulcer and appetite and decreasing blood pressure
(He et al., 2015).
Corydalis is used to treat pain, inflammation and
gastrointestinal dysfunctions. It significantly alleviates
the mechanical allodynia (Lee, Son & Kim, 2010).
Dong Quai, also known as Tang Kuei or Angelica
sinensis has blood toning and nourishing effects attributed to its vitamin B12, folic acid, folinic acid,
nicotinic acid, and biotin content (DeRosa & Cupp,
1997). The herb contains Z-ligustilide which has a
calming effect on the nervous system, promoting relaxation and reducing pain. The herb also promotes
Baptist Health South Florida
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hematopoiesis and can help increase blood volume
after injury or surgery (Chao & Lin, 2011; Deng, et al.,
2009).

of sickle cell disease patients.

Jujube is also known as Zizyphus Lotus. It is a
tropical and subtropical plant used in nutrition, health
and has antimicrobial, anti-inflammatory, hypoglycemic, antioxidant, and immunomodulatory effects
(Abdoul-Azize, 2016). Licorice root (also Szechuan
lovage or ligusticum striatum) is a flowering plant in
the carrot family which has have therapeutic properties
and is used to treat a painful swelling of the joints. It
has been shown to have triterpene saponins and flavonoids as its main bioactive compounds. This agent
stimulates immune responses and activates antioxidant
enzymes (Yang, Yuan, Ma, Zhou, & Liu, 2016).

The study population consisted of patients between ages 5 and 12 years old who were diagnosed
with sickle cell anemia and were registered at the study
site.

Poria is an extract that can help increase the indexes of phagocyte, thymus, spleen, and promotes spleen
antibody production, hemolytic activity, and delayedtype hypersensitivity (Chen, Zhang, & Cheung, 2010).
Rehmannia Root is a blood refresher and has antioxidative, anti-inflammatory and anti-apoptotic effects.
It helps to regulate deficient blood patterns such as
anemia, irregular menses, and uterine and postpartum
bleeding (Huang et al., 2013; Yuan, Yang, Han, & Ni,
2018).
Salvia miltiorrhiza is a perennial plant with active
ingredients that can cause coronary vasodilatation,
suppress thromboxane formation, inhibit platelet adhesion and aggregation, and scavenge free radicals. It
increases the activities of catalase, manganese superoxide dismutase, glutathione peroxidase, and coupled
endothelial nitric oxide synthase. (Jiang et al., 2014;
Yu et al., 2015).
White Peony (Paeonia sterniana) contains a
unique glucoside called paeoniflorin, which calms
nerves and alleviate spasm and pain (He & Dai, 2011).
Working with other glucosides to make up total glucosides of peony (TGP), it has an anti-inflammatory effect and protects against oxidative damage (Wu, Pu,
Yu & Li, 2015).
OBJECTIVES
The objective of this study was to investigate the
efficacy of a combination of the EvenFlo nutritional
supplement and the active agent, folic acid compared
to folic acid alone for the management of sickle cell
disease.

Population

Before the initiation of the clinical trial, patients at
the study site were regularly prescribed a regimen of
daily folic acid and proguanil medications. The folic
acid is intended to help replace depleted folate stores
and reduce the symptoms of anemia. Folate was expected to lead to a decrease in symptoms of anemia
and help in the prevention of hyperhomocysteinemia
that may predispose to thrombotic events, which, in
turn, may lead to painful episodes. Thus, folic acid was
the main agent used among the participants for the
management of SCD before the trial. On the other
hand, the patients were prescribed proguanil to help
protect them against the complications of plasmodium
falciparum infection as a result of parasitemia. It was
expected to prevent bone pain crises among patients in
the event they happen to experience any crisis.
Since the goal of this trial was to investigate the
effect of EvenFlo combined with folic acid versus the
standard care (stand-alone use of folic acid), we decided not to withdraw their routine prophylaxis medication. More so, a significant proportion of the study
population reported having two or more episodes of
crises in the previous six months despite their regular
care routine, hence, their qualification for participating
in the study. The above baseline clinical and prophylactic medication characteristics provided the basis for
trial of EvenFlo without changing the status quo.
Ethical considerations and consent
This study was approved by the Institutional Ethical Review Committee (ERC) at JOOTRH. The parents and guardians of the participants voluntarily presented them for inclusion in this study and signed informed consents. The consents included statements
about the rights of the subjects, information to be collected, confidentiality and the publication of this report
and any other accompanying information.
Inclusion/exclusion criteria

At the beginning of the study, an assessment tool
was deployed to obtain medical history of the patients.
The obtained history was combined with the records
available from the hospital as well as an oral interview
to screen the patients. Patients were included if they
METHODS
had two or more crises each month for the past 6
Study site
months, had moderate anemia as determined by a hemoglobin concentration between 6-8gm/dl and have a
This study was conducted at the Jaramogi Oginga
parent/guardian who lives with them and is responsible
Odinga Teaching and Referral Hospital (JOOTRH),
for transportation to and from the hospital for treatKisumu, Kenya. JOOTRH provided an ideal setting to
ment. Patients were excluded if they had a history of
conduct this study as it is a teaching hospital involved
transient ischemic attack or clinically overt cerebrovasin medical research and houses a designated SCD Clincular accident, undergoing treatment with blood transic, the Obama Children’s Clinic, with a registered list
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fusion therapy, receiving erythropoietin, experiencing
VOC or any other crises of SCD or if their predominate cause of pain is not SCD related. Also excluded were those requiring treatment for more than 3
days per week with non-steroidal anti-inflammatory
drugs (NSAIDS), receiving chronic treatment with
anticoagulants or antiplatelet drugs, diagnosed with
any other concurrent disease. The subjects whose parents or legal guardians declined to sign the consent
form were also excluded.

tem. Upon all examinations and laboratory test results
showing no present crises or diseases, each participant
received an envelope containing the medication to be
used for the next 30 days. The subjects in the intervention group received 30 capsules of Folic Acid 500 microgram (mcg) and 60 capsules of EvenFlo 500 milligram (mg). The Folic Acid was to be used once a day
and the EvenFlo twice daily. Subjects in the control
group received 30 capsules of Folic Acid (500 mg) to
be used once a day.

Sample size

Participant follow-up

Sample sizes were calculated using G*Power
(Faul, Erdfelder, Buchner & Lang, 2009). Darbari et al.
(2013) had reported that 60% of participants in a study
reported having at least one vaso-occlusive crisis that
required treatment within a twelve month period. With
this in mind, a 40 or more percentage point decrease in
vaso-occlusive crises during a study period of six
months was of interest. Thus, assuming proportion of
participants reporting crises in the control group and
the intervention group of 60% and 20% respectively,
with a two-sided significance of 0.05 and an 80% power, a minimum of 20 subjects was required per group
for a total of 40 subjects for the study.

Subjects were followed for six months with one
visit per month. At the conclusion of the first visit,
each subject was scheduled for a first follow-up visit,
to occur 4 weeks following the initial visit. During
each visit, subjects received additional supply of medication. The data from the initial visits were considered
baseline.

On the other hand, to estimate an appropriate sample size for hemoglobin concentration and weight, a
clinically significant medium effect, defined by Cohen
(1988) to be Cohen’s f of 0.25 (equivalent to 0.06 partial η2) was of interest. With two groups, measurements at 3 different points in time, 0.05 significance
level, rho (ρ) of 0.25 (a conservative approach), a conservative conventional non-sphericity correction epsilon (ε) of 0.75 and a 80% power, a minimum of 25
subjects was required per group for a total of 50 subjects for the study. Given these estimated minimum
sample sizes and the need to have a buffer in case of
attrition, 70 subjects were enrolled into the study.
Procedure and subject allocation
At the point of screening, informed consents were
obtained and the SCD statuses of the patients were
confirmed by clinicians using a multi-parameter electrophoresis machine. After each confirmation, the clinicians obtained the subject’s demographic information and scheduled their first visit.
This was a double-blind study, thus, none of the
researchers, clinicians or the guardians knew the participants enrolled in either group or were taking the
intervention capsules. Only the pharmacist who dispensed the capsules via randomization numbers was
had knowledge of subjects’ group status. Subjects were
randomized in a 1:1 ratio using stratified block randomization particularly given that this was not a large
clinical trial.
At the first visit, examinations were conducted and
clinical information obtained. Hemoglobin concentrations were measured using a Hemoglobin testing sys38
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When the subjects returned for each follow-up
visit, their clinical information were obtained and any
medical events since the previous visit were documented. Any crises or medical events that happened inbetween the visits were documented by the parents and
guardians and reported at the next visit.
Measurement
The primary outcome variable was vaso-occlusive
crisis (VOC) as characterized by excruciating pain.
These mostly include acute chest, abdominal, back and
joint pains. Reported cases of yellow eyes in either
group were not considered VOCs and were not included in our analysis. Hemoglobin concentration and
weight index data were considered secondary outcomes. These variables are adequate to assess effects
of SCD given their association with the disease (Dos,
De, Ivo, & Cople, 2018; Kazadi, Ngiyulu, GiniEhungu, Mbuyi-Muamba, & Aloni, 2017). These variables were measured during each visit.
Quality assurance
At the end of each week during the study period, a
quality assurance meeting was held with clinicians, the
first author and consulting pediatrician in order to review the activities and information collected that week.
This included the review of completed clinical research
forms, the clinicians’ examinations, decisions and the
laboratory results. Clinicians gave instructions on
swallowing of capsules and the first dose was taken at
the hospital, in the presence of an adult guardian/
parent, who was chosen as a “medication buddy” to
give the capsule at the right time and as per the instructions.
Statistical analysis
Demographic characteristics, rates of VOC experienced, hemoglobin concentration levels and weight
indices were compared between the participants in the
intervention and control groups. The rates of vasoBaptist Health South Florida
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occlusive crises experienced by the two groups were
compared using the two proportion Z-test. We used a
two-way mixed-design Analysis of Variance
(ANOVA) model to compare mean hemoglobin concentration levels and mean weights at three different
time points (baseline, after 3 months and after 6
months), from the two study groups. Time was the
within-subject factor and group was the betweensubject factor. The assumptions of the model were
examined. Statistical significance was set at p < 0.05
except for Box’s M Tests for which we used p < .001
given that Hahs-Vaughn (2016) and Tabachnick &
Fidell (2001) recommended ignoring the test or using
smaller alpha level with unequal groups due to the
test’s sensitivity. Confidence intervals (CIs) were estimated with 95% certainty. Data transformation was
considered in rectifying the violation of the normality
assumption, however, the results did not significantly
differ from those of the untransformed data; thus, the
untransformed results were retained for reasons of simplicity and the robustness of the ANOVA test. Statistical analyses were performed using SPSS 24 by IBM.
Graphs were produced using RStudio 1.1.463 (RStudio
Team, 2015).
RESULTS
A total of 120 SCD children were screened of
which 70 children meeting the age requirement of 5 to
12 years were enrolled into the study. Thirty five subjects were allocated into the treatment (envelope +
standard of care) group and 35 into the control
(standard of care) group. Thirty-two (91.4%) subjects
in the treatment group and 29 (85.7%) in the control
completed 6 months study follow-up and had complete
data for analysis (Figure 1). All subjects were of African race. The baseline characteristics were similar
between the two groups in terms of age, gender,
weight, and hemoglobin level (Table 1).
The primary outcomes data being the amount of
VOCs experienced by the subjects were compared
between the two groups. With all 27 (93.1%) of the 29
subjects in the control group experiencing at least one
form of crises by the end of the 6 months trial compared to none (0.0%) of the 32 subjects in the treat-

ment group, there was a significant difference in the
proportion of subjects that experienced at least one
VOC (proportion difference = 0.931, 95% CI = 0.93 to
1.00, Z = 7.05, p < .001). This represents a 93.1% difference in the proportions of subjects that experienced
VOCs. Further analysis of the crises experienced by
the subjects in the control group during the trial shows
that 2 (6.9%) experienced no crises, 10 (34.5%) experienced one crisis, 14 (48.3%) experienced two crises
and 3 (10.3%) experienced three crises (Table 2).
For the secondary outcome variable of hemoglobin concentration, there were no outliers, as assessed
through studentized residuals. The assumption of normality was assessed using the Kolmogorov-Smirnov
test. The assumption was partially violated with only
four of the six subgroups of data satisfying the assumption (p > .05), the remaining two subgroups otherwise. There was homogeneity of variances, as assessed by Levene's test of homogeneity of variances
(p > .05) and homogeneity of covariances as assessed
by Box's M test (p > .001). In testing if the variances
of the differences between the related groups of the
within-subject factor for all groups of the betweensubjects factor are equal, Mauchly's test of sphericity
indicated that the assumption of sphericity was met for
the two-way interaction, χ2(2) = 4.92, p = .086. For the
test of interaction effect, the results showed that there
was a statistically significant interaction between the
treatment and time, on hemoglobin level, F(2, 118) =
4.08, p = .019, partial η2 = .065. Due to the statistically significant interaction between the treatment and
time, we determined the simple main effects of group.
Data are mean ± standard error. The results showed
that hemoglobin concentration was statistically significantly higher in the intervention group at the end of the
trial (10.67 ± 0.26 g/dL) compared to the control group
(9.22 ± 0.27 g/dL), F(1, 59) = 15.17, p < .001, partial
η2 = .205 (Figure 2). The intervention group improved
their mean hemoglobin concentration from baseline by
2.92 g/dL, 95% CI [2.33, 3.51] compared to 1.77 g/dL,
95% CI [1.00, 2.54]. Mean hemoglobin concentrations
at the three periods considered are shown in table 3.
Also for weight, another secondary outcome variable, there were no outliers as assessed through the
residuals. The assumption of normality was also

Table 1: Demographic Characteristics
Variable
Age (Years)
Mean ± SD
Min
Max
Gender
Female n (%)
Race
Black/African n (%)

Intervention Group
(n=32)

Control Group
(n=29)

Total
(n=61)

8.5 ± 1.8
6.0
11.0

8.3 ± 2.1
5.0
11.0

8.4 ± 1.9
5.0
11.0

17 (53.1)

15 (51.7)

32 (52.5)

32 (100)

29 (100)

61 (100)
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Table 2: Vaso-Occlusive Crises Experienced During Clinical Trial
Number of Crises

Intervention Group

Control Group

None

32 (100.0)

29 (6.9)

One

0 (0.0)

10 (34.5)

Two

0 (0.0)

14 (48.3)

Three

0 (0.0)

3 (10.3)

*Data represent n (%)

Table 3: Estimated Marginal Means for Weight and Hemoglobin

Baseline

3 Months

6 Months

Hemoglobin Concentration (g/dL)

Weight (Kg)

Intervention Group

7.8 ± 0.3

22.2 ± 0.9

Control Group

7.5 ± 0.3

22.8 ± 0.9

Intervention Group

8.0 ± 0.3

24.8 ± 0.9

Control Group

7.5 ± 0.3

21.9 ± 0.9

Intervention Group

10.7 ± 0.3

26.6 ± 1.0

Control Group

9.2 ± 0.3

21.8 ± 0.8

*Data represent Mean ± SE.

Figure 1. CONSORT diagram for study enrollment
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Figure 2.

Figure 3.

Profile plot of hemoglobin concentration.

Profile plot of weight.

partially violated with only the three subgroups of data
from the intervention group satisfying the assumption
(p > .05) while the three subgroups from the control
violated it. There was homogeneity of variances
(p > .05) and covariances (p > .001), as assessed by
Levene's test of homogeneity of variances and Box's M
test, respectively. Mauchly's test of sphericity showed
that the assumption of sphericity was not met for the
two-way interaction, χ2(2) = 6.17, p = .046. With this
violation and the estimated value of epsilon greater
than 0.75, we adopted the Huynh-Feldt correction
based on the recommendations of Vieira (2017) and
Girden (1992). The results of the interaction test
showed that there was a statistically significant interaction between the treatment and time, on weight, F
(1.90, 112.28) = 174.98, p < .001, partial η2 = .748, ε
= .952, thus, simple main effects were determined.
Data are mean ± standard error. The results showed
that after 3 months, the intervention group had a mean
weight (24.79 ± 0.87 Kg) statistically significantly
higher than the control group (21.92 ± 0.91 Kg), F(1,
59) = 5.17, p = .027, partial η2 = .081 (Figure 3). At
the end of the 6 months trial, the intervention group
had a mean weight of 26.63 ± 0.89 Kg, which was
significantly higher than 21.79 ± 0.93Kg of the control
group, F(1, 59) = 14.19, p < .001, partial η2 = .194.
Within the six months of trial, the intervention group
increased their mean weight from the baseline by a
mean of 4.47 Kg, 95% CI [4.02, 4.92] while the control group experienced a decrease (-1.05 Kg, 95%
CI [-1.60, -0.51] in their mean weight in the same time
period. Mean weight at the three time periods considered are shown in table 3.

DISCUSSION
EvenFlo is an effective agent in reducing the frequency of sickle cell disease crises as evidenced by a
percentage difference of over 93.1% in the amount of
individuals that experience any form of crises during
the trial. While no subject experienced an episode of
VOC among the treatment group for the 6 months,
93.1% of the subjects in the control group experienced
at least one crises.
Evenflo is also effective in increasing the hemoglobin concentration of the blood for SCD patients. At
the end of the 6 months trial period, the subjects in the
intervention group had increased their hemoglobin
concentration by a mean of 2.92 g/dl; this is significantly higher than 1.77 g/dl observed among those that
took only folic acid. Similarly, the nutritional supplement saw the subjects in the intervention group
increase their mean weight from the baseline by a
mean of 4.47 Kg, while the control group experienced
a decrease of 1.05 Kg in their mean weight during the
trial period.
Overall, EvenFlo helps in the management of
SCD by preventing VOCs due to SCD, increasing
hemoglobin concentration and increasing weight; this
is consistent with the findings of Anicet et al. (2019).
We imagine that EvenFlo provides a better alternative for SCD patients than some of the options previously available. For instance, hydroxyurea is commonly used to manage SCD. With the benefits derived
from hydroxyurea also come the side effects of neutropenia, bone marrow suppression and mild peripheral
blood cytopaenia, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility (Agrawal, Patel,
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Shah, Nainiwal, & Trivedi, 2013). These side effects
are conspicuously absent with EvenFlo.
Side effects
A single participant in the treatment group had
mild diarrhoea after initiation of treatment; the diarrhoea stopped after a couple of days and the participant
continued with the treatment until the end of the study.
The diarrhoea may have been a side effect of the nutritional supplement, however, the single occurrence was
not sufficient to draw definitive conclusions. No other
possible side effect was reported.
Limitations
A limitation of the study relates to our passive
follow-up of subjects. Limitations of this approach is a
reliance on the subjects and their parents/guardians to
narrate any crises experienced between any two visits
at the next visit, there is a possibility of not been able
to capturing certain crises. A system for real-time reporting can be implemented in the future studies.
Another limitation has to do with a subjective
method of measuring compliance. We relied on the
parents/guardians to see to the proper use of the supplements and oral report of compliance. Some parents/
guardians reported that their wards had difficulty in
swallowing the capsules and we were not able to do
directly the administration of the supplements but relied on parents/guardians to administer it daily). A
tracking system can be provided to monitor compliance.
Additionally, the six month study period is somewhat short, a longer study period of 12 months or more
can be considered in the future. Also, the impact of
EvenFlo alone on SCD patients without the administration of folic acid may be explored in the future while
addressing the limitations mentioned.
Furthermore, none of female subjects in this study
was known to have started their monthly period yet.
Given that SCD is associated with delay in menarche
and gonadal dysfunction (Kopeika et al., 2019; Stimpson, Rebele, & Debaun, 2015), a study on young women and women of reproductive age may help understand the effect of this supplement on that group.
CONCLUSION
The results from this randomized controlled trial
showed that EvenFlo in addition to folic acid, is an
effective agent in the management of SCD. Thus, we
recommend the use of EvenFlo for the management of
SCD patients as its effect would be useful in significantly limiting the onset of crises suffered by these
individuals as well as boosting their hemoglobin concentration and weight indices possibly leading to improved quality of lives.
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